Login
$KPTI
$0.02 -$0.00 (7.47%) After hours

Company Executives

Management Team

From the 10-K annual report
Officer Age In this role Joined 2025 pay Source
Richard Paulson Also a director
President and Chief Executive Officer
58 Since 2021
5 years
Not stated $2,320,902
Lori Macomber
Executive Vice President, Chief Financial Officer and Treasurer
55 Since 2025
1 year
2025 Not reported
Sohanya Cheng
Executive Vice President, Chief Commercial Officer
43 Since 2021
5 years
2021 Not reported
Michael Mano
Executive Vice President, Chief Legal Officer and Secretary
49 Since 2026
this year
2020 Not reported
Stuart Poulton
Executive Vice President, Chief Development Officer
53 Since 2022
4 years
2022 $1,399,580
Reshma Rangwala
Executive Vice President, Chief Medical Officer
48 Since 2022
4 years
2022 $2,016,134
Kristin Abate
Chief Accounting Officer
Title from the Form 4 dated Oct 16, 2026
Not stated Not stated Not stated Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
8.6 years
from year joined
Director Age On board Independent Other public boards 2025 pay Source
Richard Paulson
58 2020
6 years
Not independent None stated Paid as CEO
Barry E. Greene
62 2013
13 years
Independent None stated $130,142
Christy J. Oliger
56 2020
6 years
Independent Nuvalent, Inc. $95,142
Deepika R. Pakianathan, Ph.D.
61 2013
13 years
Independent Theravance Biopharma, Inc., Mereo Biopharma Group PLC $105,142
Chen Schor
53 2020
6 years
Independent Adicet Bio, Inc. $85,142
Garen G. Bohlin
78 2013
13 years
Independent Collegium Pharmaceutical, Inc. $95,142
Zhen Su, M.D.
49 2023
3 years
Independent CytomX Therapeutics, Inc. $75,142

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

3 disclosed in the proxy filed Apr 13, 2026
Entities advised or subadvised by T. Rowe Price Investment Management, Inc. ("T. Rowe")
$4,999,999.72

Purchased 850,238 shares of common stock and warrants to purchase 753,012 shares in the October 2025 Private Placement.

J. Wood Capital Advisors LLC
Approximately $1.91 million
October 2025

Issued 326,667 shares of common stock and warrants to purchase 215,906 shares in satisfaction of consideration owed for financial advisory services in connection with the Financing Transactions.

each of our directors
each of our directors
Amount not stated

Indemnification agreements requiring the company to indemnify each director for certain expenses, judgments, fines and settlements arising from service as a director.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support